VIMIAN Share Price Performance
SEK 32.64
0.64 (2.00%)
36.8% undervalued intrinsic discount
SEK 51.65
Fair Value
Price SEK 32.64
AnalystHighTarget SEK 51.65
AnalystConsensusTarget SEK 41.65
AnalystLowTarget SEK 37.32
Fair ValueSEK 51.65
Share PriceSEK 32.64
36.8% undervalued intrinsic discount
VIMIAN Community Narratives
AN
Fair Value SEK 51.65 36.8% undervalued intrinsic discount
Emerging Pet Trends And Digital Diagnostics Will Redefine Animal Healthcare
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value SEK 41.65 21.6% undervalued intrinsic discount
Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value SEK 37.32 12.5% undervalued intrinsic discount
Rising Interest Rates And Tariffs Will Weaken US MedTech Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
VIMIAN Community Fair Values
- SEK 37.32FV12.5% undervalued intrinsic discount11.15%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrative20 days ago author updated this narrative
- SEK 51.65FV36.8% undervalued intrinsic discount12.55%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrative22 days ago author updated this narrative
- SEK 41.65FV21.6% undervalued intrinsic discount9.82%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative2users have followed this narrative5 days ago author updated this narrative
Recent VIMIAN News & Updates
No updates
Vimian Group AB (publ) Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 22, 2025
- Earnings per share (EPS)
- 0.043
- Gross Margin
- 68.74%
- Net Profit Margin
- 5.64%
- Debt/Equity Ratio
- 40.1%
Vimian Group AB (publ) Competitors
About VIMIAN
- Founded
- 2020
- Employees
- 1200
- CEO
- WebsiteView website
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.
Swedish Market Performance
- 7 Days: -2.2%
- 3 Months: 3.1%
- 1 Year: 3.0%
- Year to Date: -0.9%
Over the last 7 days, the market has dropped 2.2%, driven by a loss of 2.5% in the Industrials sector. In the last 12 months the market has been flat overall. As for the next few years, earnings are expected to grow by 17% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading